Tandem Diabetes Care climbs on FDA nod for tubeless insulin pump

** Shares of Tandem Diabetes Care TNDM.O rise 11% to $19.45

** Co says the US FDA clears Tandem Mobi as the first and only tubeless automated insulin delivery system with up to seven days of wear

** Tandem Mobi now offers both tubeless and tubed insulin delivery options, giving users flexibility to choose how they wear the pump

** Full commercial launch is planned for H1 2027 in the United States, with the sets and cartridges available exclusively through the pharmacy

** Piper Sandler analysts say the clearance is a "positive update" because investors had been wondering "why the clearance was taking so long and if something was wrong with the product," and the approval shows "that is not the case now"

** Including session moves, stock down 10% YTD